Canaccord Genuity Maintains Buy on Health Catalyst, Raises Price Target to $3
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Richard Close maintains Health Catalyst (NASDAQ:HCAT) with a Buy and raises the price target from $2 to $3.
Canaccord Genuity analyst Richard Close maintains Health Catalyst (NASDAQ:HCAT) with a Buy and raises the price target from $2 to $3.